Frequently Asked Questions
The global estrogen receptor modulators market is projected to grow at a CAGR of 9% during the forecast period of 2022-2029.
Factors such as increase in cancer cases, growing osteoporosis cases and increase in oral drugs are acting as the major drivers for the global estrogen receptor modulators market
The major players operating in the Estrogen Receptor Modulators Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Alkem Labs Ltd (India), Apotex Inc (Canada), Kyowa Kirin Co., Ltd. (Tokyo).
The major countries covered in the Estrogen Receptor Modulators Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
